Allianz Se Incyte Corp Transaction History

Allianz Se

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$65.08 - $83.38 $12,104 - $15,508	186 New	186 $12.7 Million
Q3 2024 May 12, 2025	SELL	$57.33 - $68.61 $14,332 - $17,152	-250 Reduced 26.04%	710 $46.9 Million
Q2 2024 May 12, 2025	SELL	$51.18 - $63.75 $13,818 - $17,212	-270 Reduced 21.95%	960 $58.2 Million
Q1 2024 May 12, 2025	BUY	$56.55 - $66.59 $59,038 - $69,519	1,044 Added 561.29%	1,230 $70.1 Million

740

203M

516K

265K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $19.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Allianz Se, based on Form 13F filings with the SEC.

Stay updated on Allianz Se with notifications on news.